Acid lock could fight blood infections in cancer patients

NCT ID NCT05376566

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a hydrochloric acid lock can help treat central line infections in 212 cancer and blood disease patients. The acid solution was placed in the line for 10 minutes, repeated three times, alongside standard antibiotics. The goal was to see if it reduces treatment failure, including persistent infection or the need to remove the line.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hydrochloric acid (2 M) lock solution
What this could lead to
If it works, this could provide a simple, low-cost way to treat central line infections in cancer patients, potentially reducing the need to remove the line.
What could go wrong
This is a completed trial, but the intervention is a strong acid that must be used carefully. It may not work better than standard care, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Haematology, Copenhagen University Hospital

    Copenhagen, 2100, Denmark

  • Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital

    Aarhus, 3200, Denmark

  • Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital

    Copenhagen, 2100, Denmark

  • Department of Paediatrics and Adolescent Medicine, Odense University Hospital

    Odense, 4000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.